News | Proton Therapy | October 25, 2018

New proton therapy technique could enhance dose conformity at tumor level while reducing total patient dose

Beaumont Hospital Cancer Institute Performs First Irradiation of Spot Scanning Proton Arc Therapy Plan

October 25, 2018 — IBA announced the first irradiation of a Spot Scanning Proton Arc (SPArc) plan at the Beaumont Health Proton Therapy Center in Royal Oak, Mich., on its single-room proton therapy solution Proteus One.

Proton arc therapy has the possibility to further improve the quality of the treatment by enhancing the dose conformity at the tumor level while reducing the total dose received by the patient. In addition, the Spot-Scanning Proton Arc therapy technique potentially increases the robustness of the treatment plan and may further improve the adoption of dose escalation and hypofractionation. This first irradiation achieved is the result of a long-standing research and development program between IBA and Beaumont Health’s proton therapy team.

Craig Stevens, M.D., Ph.D., chairman, radiation oncology, Beaumont Health, commented: “Beaumont Health has been leading the research in radiotherapy for decades and we have been working closely on this innovative project with IBA. Combining our expertise will bring patient treatment using proton therapy to the next level. Proton arc therapy has been contemplated for some time. The recent improvements in beam quality and delivery are enabling us to develop a clinically viable product. Spot-Scanning Proton Arc (SPArc) therapy has the potential to allow proton therapy practitioners to improve dose conformity at the tumor while further reducing dose to surrounding healthy tissue and increasing treatment effectiveness.”

See an example of proton arc therapy in the VIDEO "Beaumont's Experience With Proton Therapy After One Year" — interview with Peyman Kabolizadeh, M.D., medical director, Beaumont Proton Therapy Center.

For more information: www.iba-worldwide.com

Related Content

News | Lung Imaging

August 10, 2022 — Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 ...

Time August 10, 2022
arrow
News | Breast Imaging

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — Representatives from the Diagnostics Working Group of the IASLC Early Detection and Screening Committee ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill ...

Time August 08, 2022
arrow
News | Proton Therapy

August 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, Fred ...

Time August 05, 2022
arrow
Feature | Oncology Information Management Systems (OIMS)

August 2, 2022 — The oncology information systems market is projected to be worth $2.59 Bn by 2022 and is expected to ...

Time August 02, 2022
arrow
News | Nuclear Imaging

July 27, 2022 — Patients for Safer Nuclear Medicine, a coalition of 29 patient advocacy organizations representing ...

Time July 27, 2022
arrow
News | Radiation Oncology

July 25, 2022 — RaySearch Laboratories AB announces the launch of RayStation* 12A, the latest version of the company’s ...

Time July 25, 2022
arrow
News | PET Imaging

July 20, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 20, 2022
arrow
News | Radiopharmaceuticals and Tracers

July 20, 2022 — -NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time July 20, 2022
arrow
Subscribe Now